Physicians Use MediPines Non-Invasive Gas-Exchange Analyzer Technology to Assist with Differential Diagnosis for Pulmonary Embolism

An increasing number of physicians have been utilizing a unique gas exchange analyzer technology to enhance the recognition and diagnosis of pulmonary embolism (PE) in patients.

The device, called the MediPines AGM100, is an FDA-cleared advanced pulmonary gas exchange technology that can precisely and non-invasively measure patients’ oxygen and carbon dioxide levels in the deepest part of the lungs (alveoli), as well as oxygen deficit (alveolar-arterial difference), which support assessment of respiratory impairment.

A case study titled “Use of a Non-Invasive Pulmonary Gas-Exchange Analyzer to Improve the Pretest Probability of Pulmonary Embolism in a Patient Classified as ‘Low Risk’” by Dylan Sieck Ph.D. and Pierre Ozon, MD was presented at the American Thoracic Society (ATS) International Conference last year. Since then,  more and more clinicians and centers of excellence have been turning to the MediPines AGM100 as a diagnostic support tool to enhance recognition of PE.

PE is one of the leading causes of death in the US and the third leading cause of death in hospitalized patients. Given the possibility of asymptomatic and atypical presentation, it is generally accepted that many cases of PE go undiagnosed.

In the case study presented at ATS last year, the MediPines AGM100 device, a cardiopulmonary diagnostic support system, was shown to be a helpful adjunct tool in the diagnosis of PE and ideally suited to the task because of the quick and precise measurements it provides. The patient described in the case study was the first reported case of a non-invasive pulmonary gas-exchange analysis being used to improve pre-test probability of PE. Since then, more physicians have been turning to the technology as a diagnostic tool.

“Having an objective measure of pulmonary gas exchange impairment can factor into the diagnosis and treatment decisions that must be made in a time sensitive manner,” said Dr. Pirre Ozon, an Emergency Physician, and one of the case study’s authors. “The AGM100’s multiple measurements including oxygen deficit measurement can be highly informative in narrowing differential diagnosis scenarios similar to this case and more research is needed to fully understand its potential.”

Designated by the World Health Organization (WHO) as one of 15 notably innovative and commercially available health technologies for the treatment of COVID-19 and other global priority diseases in its 2021 edition of the WHO Compendium of Innovative Health Technologies, the MediPines AGM100 is a portable system that can be used throughout hospitals or qualified health clinics

SourceMedPines
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy